Literature DB >> 23113658

CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production.

Ryo Hatano1, Kei Ohnuma, Junpei Yamamoto, Nam H Dang, Chikao Morimoto.   

Abstract

CD26 is an activation marker of human CD4(+) T cells, and is associated with T-cell signal transduction processes as a co-stimulatory molecule. We have previously demonstrated that high CD26 cell surface expression on CD4(+) T cells is correlated with the production of T helper type 1 cytokines, whereas CD26(+) T helper cells stimulate antibody synthesis in B cells. Although the cellular and molecular mechanisms involved in CD26-mediated CD4(+) T-cell activation have been extensively evaluated by our group and others, the role of CD26 in CD8(+) T cells has not been clearly elucidated. In the present study, we examine the effector function of CD8(+) T cells via CD26-mediated co-stimulation in comparison with CD28-mediated co-stimulation. We found that CD26(high)  CD8(+) T cells belong to the early effector memory T-cell subset, and that CD26-mediated co-stimulation of CD8(+) T cells exerts a cytotoxic effect preferentially via granzyme B, tumour necrosis factor-α, interferon-γ and Fas ligand. The effector function associated with CD26-mediated co-stimulation is enhanced compared with that obtained through CD28-mediated co-stimulation, suggesting that the CD26 co-stimulation pathway in CD8(+) T cells is distinct from the CD28 co-stimulation pathway. Targeting CD26 in CD8(+) T cells therefore has the potential to be useful in studies of immune responses to new vaccine candidates as well as innovative therapy for immune-mediated diseases.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23113658      PMCID: PMC3575769          DOI: 10.1111/imm.12028

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Three memory subsets of human CD8+ T cells differently expressing three cytolytic effector molecules.

Authors:  Hiroshi Takata; Masafumi Takiguchi
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

Review 2.  Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.

Authors:  Kei Ohnuma; Nam H Dang; Chikao Morimoto
Journal:  Trends Immunol       Date:  2008-05-02       Impact factor: 16.687

3.  Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

Authors:  Elena Matteucci; Massimo Ghimenti; Serena Di Beo; Ottavio Giampietro
Journal:  J Clin Immunol       Date:  2011-09-02       Impact factor: 8.317

4.  Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis.

Authors:  J P Medema; R E Toes; C Scaffidi; T S Zheng; R A Flavell; C J Melief; M E Peter; R Offringa; P H Krammer
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

5.  Two CD95 (APO-1/Fas) signaling pathways.

Authors:  C Scaffidi; S Fulda; A Srinivasan; C Friesen; F Li; K J Tomaselli; K M Debatin; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

6.  CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 7.  Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.

Authors:  Kei Ohnuma; Nozomu Takahashi; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Front Biosci       Date:  2008-01-01

8.  Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.

Authors:  Kei Ohnuma; Masahiko Uchiyama; Tadanori Yamochi; Kunika Nishibashi; Osamu Hosono; Nozomu Takahashi; Shinichiro Kina; Hirotoshi Tanaka; Xin Lin; Nam H Dang; Chikao Morimoto
Journal:  J Biol Chem       Date:  2007-02-06       Impact factor: 5.157

Review 9.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

10.  Differential expression of CD26 on virus-specific CD8(+) T cells during active, latent and resolved infection.

Authors:  Chris C Ibegbu; Yong-Xian Xu; Dimitri Fillos; Henry Radziewicz; Arash Grakoui; Athena P Kourtis
Journal:  Immunology       Date:  2008-07-22       Impact factor: 7.397

View more
  30 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.

Authors:  Sherif S Farag; Mohammad Abu Zaid; Jennifer E Schwartz; Teresa C Thakrar; Ann J Blakley; Rafat Abonour; Michael J Robertson; Hal E Broxmeyer; Shuhong Zhang
Journal:  N Engl J Med       Date:  2021-01-07       Impact factor: 91.245

3.  Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.

Authors:  Kei Ohnuma; Ryo Hatano; Thomas M Aune; Haruna Otsuka; Satoshi Iwata; Nam H Dang; Taketo Yamada; Chikao Morimoto
Journal:  J Immunol       Date:  2015-03-18       Impact factor: 5.422

4.  Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4.

Authors:  Marcus Lettau; Michelle Dietz; Sarah Vollmers; Fred Armbrust; Christian Peters; Thi Mai Dang; Guranda Chitadze; Dieter Kabelitz; Ottmar Janssen
Journal:  Cell Mol Life Sci       Date:  2019-07-12       Impact factor: 9.261

Review 5.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

6.  Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens.

Authors:  G Elias; A Souquette; S Heynderickx; I De Meester; H Jansens; P Beutels; P Van Damme; E Smits; P G Thomas; V Van Tendeloo; B Ogunjimi
Journal:  Clin Exp Immunol       Date:  2018-09-19       Impact factor: 4.330

Review 7.  Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Hemasphere       Date:  2021-06-01

8.  Functional OCT4-specific CD4+ and CD8+ T cells in healthy controls and ovarian cancer patients.

Authors:  Jiabo Di; Leon F A G Massuger; Tjitske Duiveman-de Boer; Petra L M Zusterzeel; Carl G Figdor; Ruurd Torensma
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

Review 9.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

10.  Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.

Authors:  Núria Alonso; María Teresa Julián; Jorge Carrascal; Roger Colobran; Irma Pujol-Autonell; Silvia Rodriguez-Fernández; Aina Teniente; Marco Antonio Fernández; Antoni Miñarro; María Carmen Ruiz de Villa; Marta Vives-Pi; Manel Puig-Domingo
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.